described the results of a clinical trial using the putative histonedeacetylase(HDAC)6 inhibitor ricolinostat. However, independent lines of genetic and biochemical evidence indicate that ricolinostat is not a selective HDAC6 inhibitor and that the anti-cancer activity of this compound is a result ...
Excitingly, the TAM kinase inhibitor MRX-2843 currently in human clinical trials to treat AML and advanced solid tumors, enhances chemotherapy efficacy to further suppress Ewing sarcoma tumor growth in vivo. Our findings reveal an Ewing sarcoma chemoresistance mechanism with an immediate translational ...
In fact, early results from an ongoing clinical trial using the isotype-selective HDAC inhibitor MGCD0103 have demonstrated significant clinical responses that were associated with a decrease in serum TARC levels.33 The ability of vorinostat to inhibit TARC secretion by mDCs may also play a role...
PR-171 inhibitor The average final scores of hospitals fell within the range of 295 to 830 points, inclusive.Hospitals within the HHN's clinical demand and capacity for C-arm machines, as assessed by this analytical tool, further confirmed the imperative need for additional C-arm equipment in...
Home - ClinicalTrials.gov. https://clinicaltri als.gov/. Accessed 13 Jun 2019 17. North BJ, Almeciga-Pinto I, Tamang D et al (2017) Enhance- ment of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor. PLoS ONE 12:e0173507. https://doi. ...
At present, there is no prospective clinical trial to confirm which treatment strategy is the best after progression on CDK4/6 inhibitor. After the failure of CDK4/6i, the mPFS of chemotherapy was 4.2–5.5 months and the mPFS of endocrine therapy combined with everolimus was 4–5 months, ...
For example, in one non-limiting embodiment, the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of a STAT 6 inhibitor. The STAT 6 inhibitors of the present invention effectively inhibit the activity of the STAT 6 protein or ...
Ruxolitinib, a tyrosine kinase inhibitor selective for JAK1, 2, blocks many pro- and anti-inflammatory cytokines including IL6. Ruxolitinib has favorable pharmacodynamics and an acceptable safety profile. The short half-life (4鈥 6 h) of the drug offers the opportunity for ideal monitoring of ...
Background: Ricolinostat, an oral selective HDAC6 inhibitor, is well tolerated as monotherapy (Raje Blood 2012;120:4061) and demonstrates potent synergistic activity with lenalidomide (Len) and pomalidomide (Pom) in preclinical models (Quayle Blood 2013;122:1952). In an ongoing trial of rico...
Background: Ricolinostat, an oral selective HDAC6 inhibitor, is well tolerated as monotherapy (Raje Blood 2012;120:4061) and demonstrates potent synergistic activity with lenalidomide (Len) and pomalidomide (Pom) in preclinical models (Quayle Blood 2013;122:1952). Immunomodulatory drugs (thalidomide...